# Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

> **NCT05317819** · PHASE3 · RECRUITING · sponsor: **Polaris Group** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** ADI-PEG20
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05317819
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-14
- **Primary completion:** 2028-09
- **Final completion:** 2028-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05317819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05317819, "Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05317819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*